Funded Biotechnology Startups in Baltimore
Delfi Diagnostics closed the largest disclosed raise in this set at $225M (Series B, July 2022), with AsclepiX Therapeutics at $35M and Vita Therapeutics a…
Delfi Diagnostics closed the largest disclosed raise in this set at $225M (Series B, July 2022), with AsclepiX Therapeutics at $35M and Vita Therapeutics at $31M (Series B, October 2022) among the other eight-figure rounds. At the smaller end, Kalocyte and Melatech each recorded $10K rounds in August 2023, and NKA Bio raised a $30K seed in April of that year.
Six rounds closed in 2024 — including Rapafusyn Pharmaceuticals' $28M Series A in June and Sonavex's $15M Series A in October — making it the most active year by count in this dataset. Funding has extended into 2025, with Somnair closing a $4M seed in July and Irazu Oncology a $500K seed in March. A significant share of rounds carry a "Series Unknown" classification, and three entries show no disclosed amount, reflecting reporting gaps common in early-stage rounds.
Most recent rounds
21 shownRelated listings
Frequently asked
What are the largest disclosed rounds among Baltimore biotech companies in this dataset?
Delfi Diagnostics leads with a $225M Series B (July 2022), followed by AsclepiX Therapeutics at $35M (2020) and Vita Therapeutics at $31M (Series B, October 2022). Rapafusyn Pharmaceuticals' $28M Series A (June 2024) is the largest disclosed round from the past two years.
Which round stages appear most often in Baltimore biotech funding?
Series Unknown is the most common designation, covering nine companies including CoapTech, Emit Imaging, MyMD, Novel Microdevices, and Previse. Seed rounds appear three times (Somnair, Irazu Oncology, NKA Bio), while Series A and Series B each account for two rounds.
How active was Baltimore biotech funding in 2024 compared to other years in the data?
Six rounds closed in 2024, the highest annual count in this dataset. They span Rapafusyn Pharmaceuticals ($28M Series A, June), Sonavex ($15M Series A, October), CoapTech ($7M, September), MyMD ($7M, May), Emit Imaging ($5M, October), and Previse ($2M, October).
Are there oncology or diagnostics companies among recent Baltimore biotech raises?
Irazu Oncology raised a $500K seed in March 2025, and Rapafusyn Pharmaceuticals closed a $28M Series A in June 2024. On the diagnostics and imaging side, Delfi Diagnostics ($225M Series B, July 2022) and Emit Imaging ($5M Series Unknown, October 2024) both appear in the dataset.
What does the early-stage end of Baltimore biotech funding look like?
Seed rounds in this set range from $30K (NKA Bio, April 2023) to $4M (Somnair, July 2025), with Irazu Oncology's $500K seed (March 2025) in between. Several 2023 entries — including Kalocyte and Melatech at $10K each, both classified as Series Unknown — sit at the low end of all disclosed amounts across the 21 rows shown.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.